The product, Elute’s EP Granules with Tobramycin, is a synthetic bone filler that provides an eight-week delivery of an antibiotic while allowing bone growth, according to a Nov. 30 news release. Orthopedic surgeons Amar Ranawat, MD, of HSS and Javad Parvizi, MD, of Rothman are clinical partners in the trial.
The trials come after EP Granules with Tobramycin received investigational device exemption authorization from the FDA.
